Back HBV Treatment Approved HBV Drugs

Approved HBV Drugs

Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients

Chronic hepatitis B treatment using entecavir (Baraclude) for 1 year is good, but 3 years is better, according to an international study published in the September 2010 issue of Hepatology. Patients who received at least 3 years of cumulative entecavir therapy showed substantial histological improvement on liver biopsies and experienced regression of liver fibrosis or cirrhosis.

Read more:

Long-term Data Show Telbivudine (Tyzeka) Suppresses HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis B Patients

At the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) this month in Boston, researchers reported 4-year data from the GLOBE study, indicating that the nucleoside analog telbivudine (Tyzeka) continues to provide long-term viral load suppression, ALT normalization, and hepatitis B "e" antigen (HBeAg) seroconversion in chronic hepatitis B patients. Another study showed sustained response up to 2 years after completing telbivudine treatment.alt

Read more:

Long-term Adefovir (Hepsera) plus Emtricitabine (Emtriva) vs Adefovir Monotherapy for Chronic Hepatitis B

Antiviral therapy with nucleoside/nucleotide analog agents is effective against chronic hepatitis B virus (HBV) infection, but long-term efficacy is limited by the emergence of drug resistant virus. As reported in the May 2008 Journal of Hepatology, researchers from the University of Hong Kong conducted a trial to determine the efficacy of adefovir dipivoxil (Hepsera) plus emtricitabine (Emtriva) combination therapy in patients with chronic hepatitis B. Adefovir is currently approved for this indication; emtricitabine is approved for the treatment of HIV, but is still under investigation for HBV.

Read more:

Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?

At the annual Digestive Disease Week (DDW 2009) meeting this week in Chicago, a panel of experts discussed the prevention and management of antiviral drug resistance in patients receiving long-term treatment for chronic hepatitis B virus (HBV) infection, according to DDW Daily News, the official conference newspaper.

Read more: